ImmunityBio (IBRX) Net Income Growth (3y) (2017 - 2026)
ImmunityBio (IBRX) Net Income Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | 9.16% |
| 2 | Nanobiotix | 1,908.96 Bn | 1,908.90 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 474.03 Bn | 469.24 Bn | 1.35 Bn | 38.43% |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn | 13.80% |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | -3.84% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn | 79.26% |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | 47.10% |
| 10 | ImmunityBio | 7.20 Bn | 6.82 Bn | 43.97 Mn | -75.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -75.74% |
| Dec 31, 2025 | 16.99% |
| Sep 30, 2025 | 15.40% |
| Jun 30, 2025 | 0.80% |
| Mar 31, 2025 | -7.98% |
| Dec 31, 2024 | 13.54% |
| Sep 30, 2024 | 1.02% |
| Jun 30, 2024 | -14.62% |
| Mar 31, 2024 | -18.56% |
| Dec 31, 2023 | -50.43% |
| Sep 30, 2023 | -13.07% |
| Jun 30, 2023 | -38.51% |
| Mar 31, 2023 | -46.04% |
| Dec 31, 2022 | 0.51% |
| Sep 30, 2022 | -92.51% |
| Jun 30, 2022 | -78.47% |
| Mar 31, 2022 | -79.24% |
| Dec 31, 2021 | -47.17% |
| Sep 30, 2021 | -55.24% |
| Jun 30, 2021 | -47.72% |